Literature DB >> 26629273

Ofev (Nintedanib): First Tyrosine Kinase Inhibitor Approved for the Treatment of Patients with Idiopathic Pulmonary Fibrosis.

Loretta Fala.   

Abstract

Entities:  

Year:  2015        PMID： 26629273      PMCID： PMC4665065     

Source DB:  PubMed          Journal:  Am Health Drug Benefits        ISSN： 1942-2962


× No keyword cloud information.
  5 in total

1.  An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management.

Authors:  Ganesh Raghu; Harold R Collard; Jim J Egan; Fernando J Martinez; Juergen Behr; Kevin K Brown; Thomas V Colby; Jean-François Cordier; Kevin R Flaherty; Joseph A Lasky; David A Lynch; Jay H Ryu; Jeffrey J Swigris; Athol U Wells; Julio Ancochea; Demosthenes Bouros; Carlos Carvalho; Ulrich Costabel; Masahito Ebina; David M Hansell; Takeshi Johkoh; Dong Soon Kim; Talmadge E King; Yasuhiro Kondoh; Jeffrey Myers; Nestor L Müller; Andrew G Nicholson; Luca Richeldi; Moisés Selman; Rosalind F Dudden; Barbara S Griss; Shandra L Protzko; Holger J Schünemann
Journal:  Am J Respir Crit Care Med       Date:  2011-03-15       Impact factor: 21.405

2.  Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis.

Authors:  Ganesh Raghu; Kevin J Anstrom; Talmadge E King; Joseph A Lasky; Fernando J Martinez
Journal:  N Engl J Med       Date:  2012-05-20       Impact factor: 91.245

3.  Burden of illness in idiopathic pulmonary fibrosis.

Authors:  Harold R Collard; Alex J Ward; Stephan Lanes; D Cortney Hayflinger; Daniel M Rosenberg; Elke Hunsche
Journal:  J Med Econ       Date:  2012-04-25       Impact factor: 2.448

4.  Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis.

Authors:  Luca Richeldi; Ulrich Costabel; Moises Selman; Dong Soon Kim; David M Hansell; Andrew G Nicholson; Kevin K Brown; Kevin R Flaherty; Paul W Noble; Ganesh Raghu; Michèle Brun; Abhya Gupta; Nolwenn Juhel; Matthias Klüglich; Roland M du Bois
Journal:  N Engl J Med       Date:  2011-09-22       Impact factor: 91.245

5.  Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis.

Authors:  Luca Richeldi; Roland M du Bois; Ganesh Raghu; Arata Azuma; Kevin K Brown; Ulrich Costabel; Vincent Cottin; Kevin R Flaherty; David M Hansell; Yoshikazu Inoue; Dong Soon Kim; Martin Kolb; Andrew G Nicholson; Paul W Noble; Moisés Selman; Hiroyuki Taniguchi; Michèle Brun; Florence Le Maulf; Mannaïg Girard; Susanne Stowasser; Rozsa Schlenker-Herceg; Bernd Disse; Harold R Collard
Journal:  N Engl J Med       Date:  2014-05-18       Impact factor: 91.245
  5 in total
  11 in total

Review 1.  The Importance of Tyrosine Phosphorylation Control of Cellular Signaling Pathways in Respiratory Disease: pY and pY Not.

Authors:  Yael Aschner; Gregory P Downey
Journal:  Am J Respir Cell Mol Biol       Date:  2018-11       Impact factor: 6.914

2.  5-Aryl-1,3,4-oxadiazol-2-ylthioalkanoic Acids: A Highly Potent New Class of Inhibitors of Rho/Myocardin-Related Transcription Factor (MRTF)/Serum Response Factor (SRF)-Mediated Gene Transcription as Potential Antifibrotic Agents for Scleroderma.

Authors:  Dylan J Kahl; Kim M Hutchings; Erika Mathes Lisabeth; Andrew J Haak; Jeffrey R Leipprandt; Thomas Dexheimer; Dinesh Khanna; Pei-Suen Tsou; Phillip L Campbell; David A Fox; Bo Wen; Duxin Sun; Marc Bailie; Richard R Neubig; Scott D Larsen
Journal:  J Med Chem       Date:  2019-04-18       Impact factor: 7.446

3.  High-throughput screening discovers antifibrotic properties of haloperidol by hindering myofibroblast activation.

Authors:  Michael Rehman; Simone Vodret; Luca Braga; Corrado Guarnaccia; Fulvio Celsi; Giulia Rossetti; Valentina Martinelli; Tiziana Battini; Carlin Long; Kristina Vukusic; Tea Kocijan; Chiara Collesi; Nadja Ring; Natasa Skoko; Mauro Giacca; Giannino Del Sal; Marco Confalonieri; Marcello Raspa; Alessandro Marcello; Michael P Myers; Sergio Crovella; Paolo Carloni; Serena Zacchigna
Journal:  JCI Insight       Date:  2019-04-18

Review 4.  The Role of the Mammalian Target of Rapamycin (mTOR) in Pulmonary Fibrosis.

Authors:  Jessica Lawrence; Richard Nho
Journal:  Int J Mol Sci       Date:  2018-03-08       Impact factor: 5.923

Review 5.  A Systematic Review of the Role of Dysfunctional Wound Healing in the Pathogenesis and Treatment of Idiopathic Pulmonary Fibrosis.

Authors:  Alan Betensley; Rabab Sharif; Dimitrios Karamichos
Journal:  J Clin Med       Date:  2016-12-26       Impact factor: 4.241

6.  Self-reported Gastrointestinal Side Effects of Antifibrotic Drugs in Dutch Idiopathic Pulmonary Fibrosis patients.

Authors:  V L J Proesmans; M Drent; M D P Elfferich; P A H M Wijnen; N T Jessurun; A Bast
Journal:  Lung       Date:  2019-08-22       Impact factor: 2.584

7.  Red-COLA1: a human fibroblast reporter cell line for type I collagen transcription.

Authors:  Hui Hui Wong; Sze Hwee Seet; Charles C Bascom; Robert J Isfort; Frederic Bard
Journal:  Sci Rep       Date:  2020-11-12       Impact factor: 4.379

Review 8.  The Processes and Mechanisms of Cardiac and Pulmonary Fibrosis.

Authors:  Lucy A Murtha; Michael J Schuliga; Nishani S Mabotuwana; Sean A Hardy; David W Waters; Janette K Burgess; Darryl A Knight; Andrew J Boyle
Journal:  Front Physiol       Date:  2017-10-12       Impact factor: 4.566

9.  Protective Effects of Nintedanib against Polyhexamethylene Guanidine Phosphate-Induced Lung Fibrosis in Mice.

Authors:  Hyeon-Young Kim; Min-Seok Kim; Sung-Hwan Kim; Doin Joen; Kyuhong Lee
Journal:  Molecules       Date:  2018-08-07       Impact factor: 4.411

10.  Effects of New NSAID-CAI Hybrid Compounds in Inflammation and Lung Fibrosis.

Authors:  Laura Lucarini; Mariaconcetta Durante; Silvia Sgambellone; Cecilia Lanzi; Elisabetta Bigagli; Ozlem Akgul; Emanuela Masini; Claudiu T Supuran; Fabrizio Carta
Journal:  Biomolecules       Date:  2020-09-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.